Novartis Lost $32 Billion in a Day — Two Failed Drug Bets Exposed One Pipeline Risk

Novartis Lost $32 Billion in a Day — Two Failed Drug Bets Exposed One Pipeline Risk

**Del-desiran missed its Phase III primary endpoint days after pelacarsen disappointed, forcing investors to reassess whether an acquisition-built pipeline can offset approaching patent losses.**

*By PriceVia Global Markets Desk | Published September 9, 2026 | Updated September 9, 2026*

Why this matters now

Del-desiran missed its Phase III primary endpoint days after pelacarsen disappointed, forcing investors to reassess whether an acquisition-built pipeline can offset approaching patent losses.

Key points

- Del-desiran did not show statistically significant improvement versus placebo on the HARBOR trial’s primary endpoint. - The miss followed a setback for pelacarsen, concentrating attention on the remaining late-stage pipeline and 2030 growth target. - Novartis acquired del-desiran through its $12 billion Avidity purchase, making portfolio construction—not one trial—the deeper issue.

The numbers

| Metric | Value | Context | |---|---:|---| | Share fall | 10.9% | Reported session | | Value erased | ~$32bn | Market capitalisation | | Avidity purchase | $12bn | Del-desiran source | | Primary endpoint | Missed | Phase III HARBOR | | HARBOR enrolment | ~150 | Trial design | | Sales growth goal | 5%–6% | Annual through 2030 |

What happened

Novartis said its Phase III HARBOR study of del-desiran in myotonic dystrophy type 1 did not show a statistically significant improvement over placebo on the primary endpoint, video hand-opening time. The company observed activity in secondary and exploratory measures and will analyse the complete dataset. [S1, S2, S3] The result followed a separate setback for cholesterol drug pelacarsen. Novartis shares fell 10.9%, their worst daily decline, wiping out roughly $32 billion of market value. Del-desiran entered the portfolio through the $12 billion acquisition of Avidity Biosciences. [S1, S4]

What everyone is watching

Clinicians will examine secondary endpoints, safety and subgroup effects to determine whether any filing or additional study remains plausible. A missed primary endpoint sharply raises the bar; encouraging exploratory data cannot be treated as proof of efficacy. Investors are watching Novartis’s 5%–6% annual sales-growth target through 2030. The company needs newer medicines to offset eventual erosion from established products such as Entresto. Two setbacks in quick succession reduce the margin for further pipeline delays.

What the market may be missing

PriceVia analysis: the market reaction is about correlated portfolio risk. Novartis used acquisitions to buy late-stage growth, but paying for clinical assets does not diversify biology automatically. When multiple expected drivers fail together, investors reassess the acquisition process, probability assumptions and capital allocation. The result may also reprice the wider neuromuscular field. Competitors with different mechanisms can benefit if del-desiran exits, yet regulators and investors may apply greater scrutiny to endpoints, durability and commercial forecasts across the category.

Positive case

Secondary analyses identify a clinically meaningful population, other launches outperform and remibrutinib or earlier-stage assets fill the gap. Management maintains growth without another expensive acquisition, restoring confidence in portfolio depth.

Downside case

Del-desiran is discontinued, pelacarsen contributes little and remaining launches cannot offset patent erosion. Novartis responds with another premium-priced deal, increasing execution risk while investors cut the multiple applied to pipeline forecasts.

What would change the story

Watch the detailed HARBOR presentation, regulator discussions, impairment charges, pelacarsen analysis, remibrutinib milestones and updated 2030 guidance. A credible replacement for lost sales expectations would matter more than reassurance that the long-term target is unchanged.

Related stocks and themes

Novartis, Avidity, Dyne Therapeutics, Sarepta, rare-disease biotechnology, RNA therapeutics, clinical-trial endpoints, patent cliffs and pharmaceutical M&A.

PriceVia View

One failed trial is normal biotechnology risk; two near-simultaneous misses expose portfolio construction. The next question is not whether Novartis can explain HARBOR, but whether another asset can replace the growth investors had already priced in.

Sources and timestamps

- [S1 — Reuters: trial setbacks and market reaction](https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-announces-trial-setback-del-desiran-drug-2026-09-08/) — published 2026-09-08; accessed 2026-09-09T08:15:00+05:30 - [S2 — Novartis: HARBOR Phase III update](https://www.novartis.com/news/media-releases/novartis-provides-update-delpacibart-etedesiran-del-desiran-phase-iii-harbor-study-treatment-myotonic-dystrophy-type-1-dm1) — published 2026-09-08; accessed 2026-09-09T08:15:00+05:30 - [S3 — ClinicalTrials.gov: HARBOR study NCT06411288](https://clinicaltrials.gov/study/NCT06411288) — published accessed 2026-09-09; accessed 2026-09-09T08:15:00+05:30 - [S4 — STAT: clinical and pipeline context](https://www.statnews.com/2026/09/08/novartis-del-desiran-myotonic-dystrophy-harbor-trial-failure-neuromuscular/) — published 2026-09-08; accessed 2026-09-09T08:15:00+05:30

Visual disclosure

Hero visual created specifically for this article. Thumbnail text: “THE PIPELINE BREAKS”. It is an editorial illustration, not a market-data screenshot.

Market-risk disclaimer

This article is for market education and information only. It is not investment advice, a recommendation, or a promise of returns. Prices, transaction terms, approvals, company plans and regulations can change; verify the latest primary disclosures and assess risk independently.